{"url_path":"/sec/slbt/10-k/2026/item-3","section_key":"item-3","section_title":"Item 3 KEY INFORMATION**","topic":"sec","document":{"doc_type":"20-F","doc_date":"2026-06-18","source_url":"https://www.sec.gov/Archives/edgar/data/2070534/0001213900-26-070158-index.html","accession_number":"0001213900-26-070158","cik":"0002070534","ticker":"SLBT","issuer_name":"SL Science Holding Ltd","edgar_url":"https://www.sec.gov/Archives/edgar/data/2070534/0001213900-26-070158-index.html","primary_entity_key":"0002070534","primary_entity_name":"SL Science Holding Ltd"},"word_count":114,"has_tables":true,"body_markdown":"** **\n\n**ITEM 3. KEY INFORMATION**\n\n** **\n\n**A.**\n**[Reserved]**\n\n** **\n\n**B.**\n**Capitalization and Indebtedness**\n\nThe following table sets forth\nthe capitalization of the Company on an unaudited pro forma combined basis as of December 31, 2025, after giving effect to the Business\nCombination and the PIPE Financing.\n\n** **\n\n****\n\nAs of December 31, 2025 (pro forma)\n($ in\nthousands)\n\nCash and cash equivalents\n9,005\n\nTotal equity\n8,887\n\nDebt:\n\nNon-current debt\n65\n\nCurrent debt\n704\n\nTotal indebtedness\n769\n\nTotal capitalization\n9,656\n\n**C.**\n**Reasons for the Offer and Use of Proceeds**\n\nNot applicable.\n\n** **\n\n**D.**\n**Risk Factors**\n\nThe risk factors associated\nwith the Company are described in the Form F-4 in the section titled “Risk Factors,” which is incorporated herein by reference.\n\n1"}